The VEDS Movement is Published in an International Emergency Medicine Journal

Notebook glasses and pen

On August 25, 2019, the international Advanced Journal of Emergency Medicine (AJEM) published an article titled The Current Status of Genes and Genetic Testing in Emergency Medicine: A Narrative Review.   The article included a description of VEDS (Vascular Ehlers-Danlos Syndrome), as well as the importance of the genetic testing information to the emergency physician. We at The VEDS Movement…

Read More

The VEDS Movement Launches

Four young women sitting together smiling

The VEDS Movement is excited to announce the launch of its website for the VEDS community, “This is a huge step towards reducing the confusion between Vascular Ehlers-Danlos syndrome (VEDS) and other forms of Ehlers-Danlos Syndrome (EDS),” said Katie Wright, director of the Movement. “The website is also designed to provide the VEDS community with the most up-to-date…

Read More

New Virtual Support Groups for VEDS

Woman in pink coat in front of the computer smiling

The VEDS Movement is pleased to announce four new virtual support groups for the VEDS community. This effort is spearheaded by Katie Wright, director of The Marfan Foundation’s new VEDS division. Each support group will meet once a month using online meeting technology. Those who are unable to join online can participate by phone. “We are very excited to…

Read More

Professional Advisory Board Statement on the FDA Warning Concerning Fluoroquinolones

PAB statement on fluoroquinolones and Marfan, Loeys-Dietz, Vascular Ehlers-Danlos (VEDS)

In December 2018, the US Food and Drug Administration (FDA) issued a warning against the use of fluoroquinolones in people with Marfan syndrome and other related genetic aortic conditions. The FDA’s warning indicated that fluoroquinolones, a commonly prescribed class of antibiotics that includes Avelox, Cipro, Factive, Levaquin, and Ofloxacin, should not be used in people with certain genetic conditions…

Read More

The Marfan Foundation Adds Vascular Ehlers-Danlos Syndrome Division

The Marfan Foundation, which saves lives and improves the quality of life for people with Marfan, Vascular Ehlers-Danlos (VEDS), Loeys Dietz, and other genetic aortic conditions, is expanding with a new division dedicated to programs and support services for VEDS. The Foundation has named Katelyn Wright, a highly regarded patient advocate in the VEDS community, director of the new…

Read More

Working With Your School Nurse

young girl with medium brown hair and glasses with VEDS smiling at the camera

For parents of a child with a connective tissue condition like VEDS, worrying is a daily habit. The beginning of a new school year is especially stressful. Not only do you and your family have to get back into the routine, but you and your child also have to “break in” a new teacher and sometimes a new school…

Read More

Recording of Conference Medical Presentations Now Available

This year, for the first time, The Marfan Foundation livestreamed the medical presentations that were featured in the Annual Conference general session. Now, the recordings of these presentations are available – for free. The presentations that comprised the general session we think were most relevant to the VEDS community were: FDA Warnings and Recalls – Shaine Morris, MD, Pediatric…

Read More

The Marfan Foundation Welcomes Vascular Ehlers-Danlos Community to its 35th Annual Conference, Held in Association with Texas Children’s Hospital

The Marfan Foundation, in association with Texas Children’s Hospital, will hold its 35th Annual Conference in Houston, July 11-14, 2019, and – for the first time – a track that focuses solely on Vascular Ehlers-Danlos syndrome (VEDS), a condition related to Marfan, is offered. Nearly 75 families with VEDS, which affects about 1 in 50,000 people in the US, are already registered….

Read More

The Marfan Foundation Statement on Celiprolol

Statement from The Marfan Foundation with respect to FDA rejection of celiprolol for exclusive use in treatment of individuals with Vascular Ehlers-Danlos syndrome to prevent or control aneurysm, dissection, and rupture of major arteries On June 25, 2019, the FDA announced that it has rejected Acer Therapeutics’ application for exclusive use of the third generation beta blocker celiprolol in…

Read More